Retrospective studies supporting the use of erythropoiesis stimulating agents (ESAs) in MDS patients.
| Study group . | Study design . | N . | Results . | Comments . |
|---|---|---|---|---|
| MDS indicates myelodysplastic syndromes; ESA, erythropoiesis stimulating agent; HR, hazard ratio; CSF, colony stimulating factor; GFM, Groupe Francophone Myelodysplasies; GF, growth factor; IWG, International Working Group. | ||||
| Nordic17 | Matched cohort of ESA-treated Nordic patients to untreated Pavia patients | 121 Nordic 237 Pavia, Italy | Survival advantage for ESA-treated group (HR = .61, P = .002) | Nordic patients were treated with combination ESAs and CSFs. Survival improvement mainly in patients with low transfusion needs. |
| GFM18 | Matched cohort of ESA-treated GFM patients with untreated IMRAW patients | 403 GFM | Survival advantage for ESA-treated group (HR = .43, 95% CI: .25–.72) | GFM patients were treated with epogen or darbepoietin |
| Cleveland12 | Systematic review of 162 trials published from 1985–2005 comparing ESA-treated patients with non-GF-treated patients | 1587 ESA 1005 Non-GF | Survival advantage for ESA-treated group at 2 years follow-up (79% vs. 68%, P = .005) | Included only lower-risk MDS patients and used IWG response criteria. Differences remained significant in multivariate analyses controlling for baseline characteristic differences. |
| Study group . | Study design . | N . | Results . | Comments . |
|---|---|---|---|---|
| MDS indicates myelodysplastic syndromes; ESA, erythropoiesis stimulating agent; HR, hazard ratio; CSF, colony stimulating factor; GFM, Groupe Francophone Myelodysplasies; GF, growth factor; IWG, International Working Group. | ||||
| Nordic17 | Matched cohort of ESA-treated Nordic patients to untreated Pavia patients | 121 Nordic 237 Pavia, Italy | Survival advantage for ESA-treated group (HR = .61, P = .002) | Nordic patients were treated with combination ESAs and CSFs. Survival improvement mainly in patients with low transfusion needs. |
| GFM18 | Matched cohort of ESA-treated GFM patients with untreated IMRAW patients | 403 GFM | Survival advantage for ESA-treated group (HR = .43, 95% CI: .25–.72) | GFM patients were treated with epogen or darbepoietin |
| Cleveland12 | Systematic review of 162 trials published from 1985–2005 comparing ESA-treated patients with non-GF-treated patients | 1587 ESA 1005 Non-GF | Survival advantage for ESA-treated group at 2 years follow-up (79% vs. 68%, P = .005) | Included only lower-risk MDS patients and used IWG response criteria. Differences remained significant in multivariate analyses controlling for baseline characteristic differences. |